Hepatitis E Vaccines Market Size, Share & Industry Analysis, By Technology (Recombinant Vaccines, Viral-vector Vaccines, Nucleic-acid Vaccines, and Others), By Age Group (Pediatric and Adults), By Presentation (Prefilled Syringes, Vials, and Others), By Route of Administration (Intramuscular and Others), By Distribution Channel (Government & Public-health Procurement, International & Humanitarian Procurement, Hospitals & Vaccination Centers, Private & Travel Clinics, and Others), and Regional Forecast, 2026-2034

The hepatitis E vaccines market size was valued at USD 22.7 million in 2025. The market is projected to grow from USD 25.9 million in 2026 to USD 69.8 million by 2034, exhibiting a CAGR of 13.19% during the forecast period.

The market is poised for significant growth due to the continued burden of hepatitis E infections, recurring disease outbreaks in vulnerable regions, and increasing emphasis on vaccination as a preventive measure in high risk groups. Vaccine manufacturers and public health organizations are focusing on strengthening clinical evidence, expanding outbreak-response vaccination, evaluating vaccination strategies for high risk populations, and improving access to hepatitis E vaccines across endemic regions. Furthermore, increasing recognition of severe risk of hepatitis E among pregnant women, growing use of vaccination during humanitarian outbreaks, and continued clinical research evaluating new vaccination approaches are also expected to support the overall growth of the market.

Furthermore, major players, such as Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Zydus Lifesciences Limited, China National Biotec Group Company Limited, and GSK plc, are actively participating in strategic collaborations and acquisitions to expand their offerings, facilitate interchangeability, enhance market access, and strengthen their market presence.

HEPATITIS E VACCINES MARKET TRENDS

Evidence-based Shift Toward More Deployable Schedules and Presentations to Emerge as a Key Market Trend

The market is witnessing a gradual shift toward more operationally feasible vaccination schedules and deployment-ready product formats, particularly for use during outbreaks and humanitarian emergencies. The currently licensed Hecolin vaccine follows a three-dose schedule at 0, 1, and 6 months, which can create implementation challenges in settings characterized by population displacement, limited healthcare infrastructure, and the need for rapid protection. Growing clinical and real-world evidence supporting shorter schedules is therefore encouraging public-health authorities to consider vaccination approaches that can achieve protection within a shorter period and improve completion rates. As additional evidence accumulates, greater emphasis on simplified schedules and field-suitable presentations is expected to improve vaccine accessibility and support broader use across endemic and outbreak-prone regions. 

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Expansion of Geographic Approvals and Commercial Access to Drive Market Growth

The hepatitis E vaccines market growth is driven by increasing efforts to expand regulatory approvals and commercial availability of hepatitis E vaccines beyond their historically limited markets. Hecolin remains the principal commercially available hepatitis E vaccine, and its limited geographic availability has restricted vaccination uptake across several countries where hepatitis E remains a significant public-health concern. Expansion into additional endemic and outbreak-prone countries can increase the addressable population, enable governments and healthcare organizations to procure the vaccine, and support its inclusion in targeted HEV immunization and outbreak-response programs. Therefore, continued geographic expansion and improvement in commercial access are expected to increase vaccine utilization and support the overall growth of the market. 

MARKET RESTRAINTS

Limited Regulatory Reach and Narrow Routine-Immunization Adoption to Restrain Market Growth

The market is expected to face restraints owing to limited regulatory approvals, lack of broad WHO prequalification coverage, and the absence of hepatitis E vaccination from routine national immunization programs across most countries. WHO prequalification is important for facilitating vaccine procurement by UN agencies and supporting wider international deployment. Furthermore, WHO policy has historically not recommended hepatitis E vaccine for widespread routine national immunization. Similarly, more recent recommendations have focused primarily on outbreak response and vaccination of vulnerable populations in fragile or conflict-affected settings. Consequently, demand remains concentrated around selected countries, high-risk populations, and outbreak-response programs. This limits predictable vaccine volumes and can discourage manufacturers from making substantial commercial investments in additional production, registrations, and geographic expansion.

MARKET OPPORTUNITIES

Global Stockpile and Humanitarian Deployment to Create Significant Market Growth Opportunities

The market is expected to witness growth opportunities through development of global emergency vaccine stockpiles and increasing deployment of vaccines in humanitarian and outbreak settings. Hepatitis E outbreaks disproportionately affect populations living in refugee camps, internally displaced-person camps, conflict-affected regions, and areas with inadequate access to clean water and sanitation. Establishment of dedicated vaccine stockpiles can reduce delays associated with manufacturing lead times and emergency procurement, while enabling governments and humanitarian organizations to access vaccines when outbreaks occur rapidly. In addition, increasing deployment through organizations such as World Health Organization (WHO), United Nations International Children's Emergency Fund (UNICEF), Médecins Sans Frontières (MSF), and national health ministries can generate real-world effectiveness and safety evidence, support wider policy acceptance, and create recurring institutional procurement opportunities. Therefore, expansion of emergency stockpile mechanisms and humanitarian vaccination programs could gradually transform hepatitis E vaccines from a largely localized commercial product into an important component of global outbreak preparedness.

MARKET CHALLENGES

Limited Government Funding and Competing Immunization Priorities to Constrain Vaccine Procurement

The market faces a significant challenge from limited public-health funding and competition for resources from established immunization programs. Hepatitis E disproportionately affects low-resource, fragile, and humanitarian settings, where governments and donor organizations must simultaneously finance routine childhood vaccination, polio eradication, disease control, HPV vaccination, malaria vaccination, and emergency outbreak responses. As a result, hepatitis E vaccine procurement can receive lower priority when national immunization budgets are constrained. Limited and unpredictable funding may therefore reduce routine purchasing volumes, delay establishment or replenishment of vaccine stockpiles, and discourage manufacturers from expanding production and registration into additional countries, thereby challenging overall market growth.

• For instance, in April 2025, WHO, UNICEF, and Gavi warned that global immunization programs were facing increasing pressure from funding reductions. A WHO assessment involving 108 country offices, primarily in low- and lower-middle-income countries, found that nearly half were experiencing moderate-to-severe disruptions to vaccination campaigns, routine immunization, or access to vaccine supplies due to reduced donor funding. Such funding pressures can be particularly challenging for comparatively newer and outbreak-focused vaccines such as hepatitis E vaccines, as governments may prioritize vaccines already embedded within national immunization schedules.

Segmentation Analysis

By Technology

Commercial Availability and Established Clinical Evidence Supports Dominance of Recombinant Vaccines Segment

Based on the technology, the market is categorized into recombinant vaccines, viral-vector vaccines, nucleic-acid vaccines, and others.

The recombinant vaccines segment dominated the market in 2025 owing to the established commercial availability and extensive clinical evidence supporting recombinant HEV vaccines. The currently available hepatitis E vaccine, HEV239/Hecolin, is based on a recombinant portion of the HEV capsid protein produced using an E. coli expression system. Since recombinant technology forms the basis of the principal commercial hepatitis E vaccine and has demonstrated strong immunogenicity and protective efficacy in large clinical studies, healthcare providers and public-health organizations have greater experience and confidence in this technology compared with viral-vector or nucleic-acid approaches that remain largely developmental. Consequently, established manufacturing know-how, accumulated safety data, and real-world deployment have resulted in segment dominance.

• For instance, in 2022, Médecins Sans Frontières and the South Sudan Ministry of Health conducted the world's first reactive mass hepatitis E vaccination campaign in Bentiu using Hecolin, the recombinant HEV239 vaccine. The campaign demonstrated that recombinant hepatitis E vaccination could be practically deployed during an active outbreak, further strengthening the technology's position in the market.

The nucleic-acid vaccines segment is expected to grow at a CAGR of 80.22% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Age Group

Established Adult Indication and Higher Disease-risk Exposure to Drive Dominance of Adults Segment

Based on age group, the market is segmented into pediatrics and adults.

In 2025, the adults segment dominated the market primarily due to existing regulatory approvals, clinical evidence, and vaccination recommendations being concentrated on adult populations. Hecolin has historically been licensed for individuals aged 16 years and above, while WHO has cited insufficient information for routine vaccination of children below 16 years. In addition, several groups with elevated exposure or complication risks including food handlers, animal workers, military personnel, women of reproductive age, and travelers to endemic areas are predominantly adults. This creates a substantially larger immediately eligible population and directs most current vaccine utilization toward adults, thereby supporting the segment's dominant market position.

• For instance, WHO's 2024 hepatitis E vaccine assessment specifically evaluated vaccination of women of childbearing age aged 16 years and above in fragile and conflict-affected settings. The policy focus on an adult high-risk population demonstrates how current hepatitis E vaccination strategies remain concentrated largely within adult age groups.

The pediatric segment is projected to grow at an 87.95% CAGR during the forecast period.

By Presentation

Convenience, Dose Accuracy, and Improved Injection Safety to Support Dominance of Prefilled Syringes Segment

Based on presentation, the market is segmented into prefilled syringes, vials, and others.

Prefilled syringes segment held the largest hepatitis E vaccines market share in 2025 owing to presentation of established HEV239 vaccine in a ready-to-administer single-dose format. WHO documentation states that Hecolin is supplied in a prefilled syringe, which reduces vaccine preparation requirements before administration. This format can simplify workflow at vaccination sites, provide a standardized dose, reduce handling requirements, and support faster administration compared to presentations requiring withdrawal from multidose vials. These advantages are particularly important for private vaccination centers, mass vaccination campaigns, and emergency settings, resulting in greater utilization of prefilled syringes and supporting the segment's leading market position.

• For instance, in November 2023, Xiamen Innovax Biotech completed production of first batches of Hecolin incorporating an upgraded safety device for its prefilled syringe presentation. According to the company, the mechanism covers the needle after activation. It helps reduce accidental needlestick injuries and syringe reuse, demonstrating continued investment in improving the usability and safety of the dominant vaccine presentation.

The others segment is projected to grow at a CAGR of 65.62% during the forecast period.

By Route of Administration

Established Product Labeling and Extensive Clinical Use to Sustain Dominance of Intramuscular Administration

Based on route of administration, the market is segmented into intramuscular and others.

Intramuscular segment dominated the market as the commercially established hepatitis E vaccination regimen has been developed, evaluated, and approved using this route. WHO specifies that HEV239/Hecolin is administered through intramuscular injection, traditionally as three 0.5 mL doses at 0, 1, and 6 months. Extensive efficacy, safety, and vaccine immunogenicity evidence has therefore been generated using intramuscular administration, reducing the need for healthcare providers to shift toward alternative delivery routes. Moreover, intramuscular injection is widely established within vaccination practices and does not require specialized alternative-delivery infrastructure, thereby supporting its dominant share.

• For instance, in August 2025, URIHK Pharmaceuticals launched Hevrevac in India, a recombinant hepatitis E vaccine approved for active immunization of adults aged 18–65 years. The company specifies a three-dose regimen at 0, 1, and 6 months, with each 0.5 mL dose administered through intramuscular injection in the deltoid region. The commercial introduction of a hepatitis E vaccine using the intramuscular route further demonstrates the route’s established suitability for standardized vaccine administration and supports its dominant position in the market.

The others segment is projected to grow at a CAGR of 76.45% during the forecast period.

By Distribution Channel

Traveler-focused Vaccination and Limited Routine Immunization to Drive Dominance of Private & Travel Clinics Segment

Based on distribution channel, the market is segmented into government & public-health procurement, international & humanitarian procurement, hospitals & vaccination centers, private & travel clinics, and others.

The private & travel clinics segment dominated the market owing to the historically limited incorporation of hepatitis E vaccination into routine government immunization programs and the strong relevance of vaccination among individuals traveling to endemic or outbreak-prone regions. WHO has not historically recommended broad introduction of hepatitis E vaccination into routine national immunization programs, resulting in a relatively large proportion of commercially driven vaccination being associated with targeted risk-based use rather than universal population vaccination. At the same time, the manufacturer's product information identifies travelers to hepatitis E endemic regions among populations relevant to Hecolin. Consequently, private vaccination centers and travel-health clinics provide an important point of access for individuals seeking preventive vaccination before travel or due to occupational and personal risk, supporting the segment's leading market position.

• For instance, in March 2026, Fortis Healthcare highlighted the availability of the newly approved hepatitis E vaccine at major hospitals, including Fortis Hospital Mohali, and identified travelers to hepatitis E-endemic regions among the populations that could benefit from vaccination. The availability of the vaccine through hospital-based and private preventive-care settings demonstrates the growing role of private healthcare and travel-related vaccination channels in providing access outside broad routine immunization programs, thereby supporting the segment’s market position.

The others segment is projected to grow at a CAGR of 14.96% over the forecast period.

Hepatitis E Vaccines Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America was valued 0.08 million in 2024 and maintained its value in 2025 at USD 0.10 million. The regional market is expected to grow from a relatively low base owing to increasing awareness of travel-associated HEV infection and recognition of sporadic zoonotic cases. As no hepatitis E vaccine is currently approved in the U.S., future regulatory approvals and travel-health adoption provide considerable room for market expansion.

U.S. Hepatitis E Vaccines Market

Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is estimated at around USD 0.13 million in 2026, accounting for roughly 0.49% of the global market.

Europe

Europe is projected to grow at a CAGR of 27.14% over the forecast period and will reach a valuation of USD 0.23 million by 2026. The Europe market is anticipated to grow owing to increasing surveillance of locally acquired hepatitis E and greater recognition of zoonotic and foodborne HEV transmission. European Centre for Diseases Control and Prevention (ECDC's) continued focus on HEV surveillance and at-risk populations is expected to strengthen disease identification and create opportunities for preventive vaccination strategies.

U.K. Hepatitis E Vaccines Market

The U.K. market is estimated at USD 0.03 million in 2026, accounting for roughly 0.12% of the global market.

Germany Hepatitis E Vaccines Market

Germany's market is projected to reach approximately USD 0.04 million in 2026, equivalent to around 0.14% of the global market.

Asia Pacific

Asia Pacific is estimated to reach USD 22.14 million in 2026 and secure the dominant position in the market. Asia Pacific is expected to remain a key growth region owing to the high hepatitis E disease burden in East and South Asia, established vaccine availability, and expanding commercialization across endemic countries. China’s established use of Hecolin, combined with growing regional awareness and opportunities for additional country approvals, is supporting vaccine uptake.

Japan Hepatitis E Vaccines Market

The Japanese market in 2026 is estimated at around USD 0.19 million, accounting for approximately 0.74% of the global market.

China Hepatitis E Vaccines Market

China's market is projected to be among the largest worldwide, with 2026 revenues estimated at around USD 18.14 million, accounting for approximately 70.02% of global sales.

India Hepatitis E Vaccines Market

The Indian market in 2026 is estimated at around USD 0.65 million, accounting for roughly 2.51% of global revenue.

Latin America and Middle East & Africa

Latin America is expected to witness moderate growth in this market during the forecast period. The market in Latin America is estimated to reach a valuation of USD 0.18 million in 2026. The market is expected to grow owing to contaminated water and zoonotic HEV transmission and improving surveillance of an historically underdiagnosed infection. Evidence of HEV circulation across humans, animals, and environmental sources creates opportunities for stronger prevention programs and future vaccine introduction. In the Middle East & Africa, the GCC is set to reach USD 0.14 million in 2026.

South Africa Hepatitis E Vaccines Market

The South African market is projected to reach approximately USD 0.11 million by 2026, accounting for roughly 0.43% of global revenue.

COMPETITIVE LANDSCAPE

Key Industry Players

Commercial Concentration and Clinical Pipeline Advancement by Key Companies to Intensify Market Competition

The hepatitis E vaccines market is highly concentrated, with competition currently centered on a limited number of commercially available products and clinical-stage vaccine programs. Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., through its vaccine subsidiary Xiamen Innovax Biotech Co., Ltd., maintains a strong position in the market through Hecolin. Zydus Lifesciences Limited is emerging as an important clinical-stage participant and has advanced its recombinant hepatitis E vaccine through Phase II clinical development in India.

Other vaccine manufacturers have comparatively limited or legacy participation in the hepatitis E vaccine landscape. China National Biotec Group Company Limited (CNBG) has extensive vaccine development and manufacturing capabilities through subsidiaries including the Changchun Institute of Biological Products, which historically participated in hepatitis E vaccine development. Therefore, established product availability, regulatory expansion, clinical evidence generation, pipeline progression, and access to endemic markets are expected to remain the major competitive differentiators within the market.

LIST OF KEY HEPATITIS E VACCINES COMPANIES PROFILED

• Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (China)
• Zydus Lifesciences Limited. (India)
• China National Biotec Group Company Limited (China)
• GSK plc (U.K.)

KEY INDUSTRY DEVELOPMENTS

• June 2026: Xiamen Innovax Biotech announced publication of results from a multicenter Phase IV study evaluating co-administration of its Hecolin hepatitis E vaccine and Cecolin bivalent HPV vaccine. The study enrolled 480 women aged 18–25 years and reported 100% seroconversion after completion of vaccination, while supporting the potential for more convenient combined vaccination strategies among women of reproductive age.
• June 2026: Xiamen Innovax Biotech held discussions with a delegation from the Consulate General of Pakistan in Guangzhou regarding further vaccine cooperation. The discussions specifically covered the further promotion and application of Hecolin in Pakistan, clinical research involving special populations, and additional public-health cooperation, strengthening the company's efforts to expand the international utilization of its hepatitis E vaccine.
• January 2026: Reddy’s Laboratories launched Hevaxin, a recombinant hepatitis E vaccine, in India following approval for active immunization against HEV infection in adults aged 18–65 years. The company also disclosed partnerships with Shenzhen Mellow Hope Pharm and URIHK Pharmaceutical for the marketing and distribution of Hevaxin in India, expanding commercial access to hepatitis E vaccination in the country.
• August 2025: Zydus Lifesciences reported the completion of Phase II clinical trials for its hepatitis E vaccine as part of its Vaccines R&D update. The milestone advances another recombinant hepatitis E vaccine program through clinical development. It indicates the potential emergence of additional commercial competition in a market historically characterized by very limited product availability.

REPORT COVERAGE

The hepatitis E vaccines market report provides market size estimates and forecasts for all segments covered in the study, including technology, age group, presentation, route of administration, distribution channel, and geography. The market outlook also evaluates the key drivers, restraints, opportunities, challenges, and emerging trends expected to influence market growth during the forecast period. It provides information on the rising burden of hepatitis E, recurring outbreaks in endemic and humanitarian settings, expanding vaccine access, evolving vaccination schedules, regulatory approvals, and increasing public-health focus on high-risk population vaccination across major regions and countries. The report further examines important industry developments, including product launches, clinical-trial advancements, geographic approvals, humanitarian vaccination programs, global stockpile initiatives, collaborations, partnerships, and distribution agreements. It also presents a comprehensive global market analysis and a detailed competitive landscape covering estimated market shares, vaccine portfolios, pipeline products, business strategies, geographic presence, recent developments, and profiles of key market participants.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1:  Company and Product Revenue-Attribution Model

• Collection of company revenue, annual reports, exchange filings, investor presentations, official product disclosures, and vaccine portfolio information.
• Estimation of HEV-attributable revenue from the vaccine segment revenues of key companies such as Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., and others.
• The summation of various companies’ Hepatitis E vaccines sales revenues allowed us to arrive at the total market for Hepatitis E.

Approach 2: Eligible Population, Vaccination-Coverage and Dose-Consumption Model

• Identification of countries with verified approval, import permission, procurement, humanitarian deployment, or special-access demand.
• The estimations of eligible adult/pediatric populations based on current labels and modeled future age expansion.
• The estimation of vaccinated people was conducted using the factors of eligible population, accessibility, uptake, actual coverage, this was then converted to commercial doses using the data such as schedule completion.
• This total number of doses was then converted from commercial doses to manufacturer-level revenue using country-specific net prices and allocation by segmentation and geography.

Approach 3:  Procurement, Tender and Outbreak-Deployment Model

• Collection of public-health procurement, humanitarian purchases, outbreak-response orders, tenders and known campaign dose volumes.
• Recording of supplier, product, presentation, volume, price/contract value, delivery period and procurement organization wherever available.
• Estimation of outbreak demand from target population, coverage, doses per vaccinated person and campaign timing.
• This number of doses was then multiplied with the ASP at the manufacturer’s level to arrive at the global market.

2. Top Down Approaches

Approach 1: Analysis of Parent Markets and Credible Secondary Sources and Institutional Data

• Estimation and analysis of parent markets such as the global and regional vaccines markets to estimate the value share attributable to Hepatitis E vaccines.
• Analysis of data from WHO, SAGE, GACVS, WHO Prequalification, UNICEF/Gavi, national health agencies and regulators as the mandatory evidence-validation layer.
• Validation of disease burden, product status, regulatory approvals, age indication, schedule, presentation, procurement mechanisms, clinical evidence, post-market safety and pipeline timing.
• Analysis of company filings, clinical-trial registries, public tenders, price lists, manufacturing disclosures and trade evidence.

3. List of Key Sources

• Annual reports, SEC/exchange filings, investor presentations, earnings disclosures, sustainability reports, and product-specific revenue disclosures.
• Company press releases covering product launches, capacity expansions, manufacturing investments, acquisitions, partnerships, and supply agreements.
• WHO, SAGE, GACVS, WHO Prequalification, Gavi and UNICEF
• NMPA, CDSCO/DCGI, FDA/CBER, EMA/EC, PMDA/MHLW, TGA
• CDC, PHAC, ECDC, UKHSA, RKI, NIID, national ministries/surveillance agencies
• Company annual reports, stock-exchange filings, product labels, official price lists and clinical-trial registries
• Public tenders, import licenses, batch-release and outbreak-deployment records.
• Public procurement portals, tender databases, customs/import-export databases, and manufacturing registries.
• Biopharmaceutical manufacturing capacity, vaccine manufacturing, cell & gene therapy, and CDMO facility disclosures.

4. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents:
  • Vaccine manufacturers/product owners, importers, distributors, procurement specialists and regulatory/market-access experts.

Demand Side Interviews: 40%

• Key Respondents:
  • Public-health programme managers, humanitarian vaccinators, infectious disease physicians, travel clinics and hospital vaccination centers.